Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Study: Omega-3 fatty acids may help improve treatment response, quality of life for patients with cancer

Adding omega-3 fatty acids to anti-tumor medications may improve treatment response and quality of life for cancer patients according to a new study by researchers at the University Hospitals of Leicester in the United Kingdom.

28 Jul 2015

New paper describes positive effects of CRAC channel inhibitors in animal models of acute pancreatitis

Researchers from CalciMedica, Inc. and the University of Liverpool today announced the publication of a paper describing positive effects of calcium release-activated calcium (CRAC) channel inhibitors in animal models of acute pancreatitis. The paper, titled "Inhibitors of ORAI1 prevent cytosolic calcium-associated injury of human pancreatic acinar cells and acute pancreatitis in 3 mouse models" appears in the August edition of the journal Gastroenterology.

25 Jul 2015

Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

Although some previous studies have suggested an increased risk of bladder cancer with use of the diabetes drug pioglitazone, analyses that included nearly 200,000 patients found no statistically significant increased risk, however a small increased risk could not be excluded, according to a study in the July 21 issue of JAMA.

22 Jul 2015

UCLA scientists identify new method to deliver glucose to pancreatic and prostate cancer cells

UCLA scientists have for the first time identified a new sodium-dependent mechanism to deliver glucose—the body's main fuel that drives tumor growth—to pancreatic and prostate cancer cells, offering new hope in the fight against two of the deadliest forms of the disease.

21 Jul 2015

NeoGenomics announces launch of new germline cancer predisposition testing services

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new tests include comprehensive testing for BRCA1 and BRCA2 encompassing an analysis of all exons and adjacent intronic regions.

20 Jul 2015

Magnetic nanoparticles may hold key to bringing immunotherapy into successful clinical use

In recent years, researchers have hotly pursued immunotherapy, a promising form of treatment that relies on harnessing and training the body's own immune system to better fight cancer and infection. Now, results of a study led by Johns Hopkins investigators suggests that a device composed of a magnetic column paired with custom-made magnetic nanoparticles may hold a key to bringing immunotherapy into widespread and successful clinical use.

16 Jul 2015

Canadian researchers launch world's first viral therapy clinical trial to attack and kill cancer cells

Canadian researchers have launched the world's first clinical trial of a novel investigational therapy that uses a combination of two viruses to attack and kill cancer cells, and stimulate an anti-cancer immune response. Previous research by this team and others worldwide suggests that this approach could be very powerful, and could have fewer side effects than conventional chemotherapy and radiation, although it will take years to rigorously test through this trial and others.

13 Jul 2015

Researchers develop novel technique to generate activated T cells to tackle advanced melanoma

T cells from patients with melanoma can trigger a protective immune response against the disease according to a new study out of University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine.

8 Jul 2015

Researchers identify better way to screen for lung cancer

The Valley Hospital in Ridgewood, NJ, is pleased to announce that two of its oncologists and a research scientist are helping pave the way to an easier, more accurate, less invasive way to screen for the most common form of lung cancer. Lung cancer is the most common cancer in men worldwide and the number one cancer killer in the United States.

30 Jun 2015

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun a new Phase Ib/II clinical trial using a new immunotherapy treatment for patients with advanced kidney, non-small cell lung cancer, pancreatic cancer and colorectal carcinoma.

27 Jun 2015

IU researchers find that microRNA-29 may be potent therapeutic target against pancreatic cancer

Indiana University cancer researchers found that a particular microRNA may be a potent therapeutic agent against pancreatic cancer. The research was published June 22 in the journal Scientific Reports.

26 Jun 2015

New chemical compound reduces pancreatic cancer tumour growth by 80% in mice

Scientists from UCL (University College London) have designed a chemical compound that has reduced the growth of pancreatic cancer tumours by 80 percent in treated mice.

26 Jun 2015

Gene-encoded protein may be effective in early detection of pancreatic cancer

A protein encoded by the gene glypican-1 (GPC1) present on cancer exosomes may be used as part of a potential non-invasive diagnostic and screening tool to detect early pancreatic cancer, potentially at a stage amenable to surgical treatment, according to a study at The University of Texas MD Anderson Cancer Center.

24 Jun 2015

Johns Hopkins researchers identify multiple genetic changes that may increase risk of pancreatic cancer

In a genome-wide association study believed to be the largest of its kind, Johns Hopkins researchers have uncovered four regions in the human genome where changes may increase the risk of pancreatic cancer.

24 Jun 2015

Study suggests that blood clots in abdominal vein could be an indicator of undiagnosed cancer

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), concludes that a blood clot in an abdominal vein may be an indicator of undiagnosed cancer. The study also suggests that these clots predict poorer survival in patients with liver and pancreatic cancer.

19 Jun 2015

Canadian and Israeli researchers meet to discuss underlying mechanisms that drive pancreatic cancer

Leading Canadian and Israeli scientists gathered at the Hebrew University of Jerusalem's Faculty of Medicine to attend a forum on pancreatic cancer research and help dedicate the Alex U. Soyka Pancreatic Cancer Research Project.

18 Jun 2015

New open access journal to deliver case reports on all aspects of pancreatic cancer

Case Reports in Pancreatic Cancer, a new peer-reviewed, open access journal from Mary Ann Liebert, Inc., publishers, will deliver authoritative case reports on all aspects of pancreatic cancer diagnosis, management, treatment, and outcomes.

17 Jun 2015

Study: Nut consumption associated with decreased risk of some types of cancer, but not type 2 diabetes

Cancer and type 2 diabetes are two of the most significant public health burdens facing the world today, and currently available data suggests their prevalence is expected to continue to increase. Nut consumption has long been hypothesized to have a role in preventing both of these diseases, but until now evidence has been inconsistent.

17 Jun 2015

Glucose-control drug sitagliptin does not raise risk of cardiovascular events

A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events.

9 Jun 2015

Sanofi announces results from Phase IIIb ELIXA study of Lyxumia in adults with diabetes and high CV risk

Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide) in adults with type 2 diabetes and high CV risk.

8 Jun 2015